Strategic Global Advisors LLC Cuts Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Strategic Global Advisors LLC decreased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 34.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,342 shares of the specialty pharmaceutical company's stock after selling 5,858 shares during the quarter. Strategic Global Advisors LLC's holdings in Jazz Pharmaceuticals were worth $1,397,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Bessemer Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock valued at $3,317,000 after acquiring an additional 92 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Jazz Pharmaceuticals by 5.2% in the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after acquiring an additional 97 shares during the last quarter. Synovus Financial Corp lifted its stake in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock worth $2,365,000 after buying an additional 100 shares during the last quarter. Quarry LP grew its position in Jazz Pharmaceuticals by 6.3% during the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock worth $209,000 after buying an additional 100 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer now directly owns 439,307 shares in the company, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Seamus Mulligan acquired 1,621 shares of the business's stock in a transaction dated Monday, May 12th. The stock was acquired at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the transaction, the director now owns 101,621 shares in the company, valued at approximately $10,466,963. The trade was a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 28,236 shares of company stock worth $3,956,190 in the last ninety days. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Up 0.5%

Shares of JAZZ stock traded up $0.58 during trading hours on Friday, reaching $108.40. The company had a trading volume of 331,513 shares, compared to its average volume of 848,707. The company has a market cap of $6.68 billion, a price-to-earnings ratio of 15.29, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The business has a fifty day simple moving average of $113.50 and a 200-day simple moving average of $121.91.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business's revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.68 EPS. On average, research analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on JAZZ shares. Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Morgan Stanley dropped their target price on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.